<DOC>
	<DOC>NCT00358540</DOC>
	<brief_summary>The study will evaluate the safety and tolerability, optimal biologic dose, and pharmacokinetics of eltrombopag for patients with advanced sarcoma who have a low platelet count and are receiving ADRIAMYCIN and ifosfamide (AI) chemotherapy.</brief_summary>
	<brief_title>Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion criteria: Adult subjects, 18 years or older Adequate liver and kidney function Prior history of ≥grade 2 thrombocytopenia (platelet nadir ≤ 75,000/microliters) Ability to ingest and retain oral medication Practice acceptable birth control Ability to understand and follow study requirements Life expectancy of at least 3 months Exclusion criteria: History of platelet disorders, dysfunction, or a bleeding disorder Anticoagulant used within 2 weeks prior to study start Females who are lactating or expecting History of thromboembolic events or drug induced thrombocytopenia History of central nervous system, brain and/or leptomeningeal metastases Prior surgery within 2 weeks or radiotherapy within 4 weeks of study start Preexisting cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>thrombopoiesis</keyword>
</DOC>